|
|
GW Pharmaceuticals PLC - Comparative Business Analysis Snapshot
Business Description
GW Pharmaceuticals PLC. The Group's principal activity is developing a range of new medicines based on cannabis and other controlled drugs. The Group's lead programme is the development of a portfolio of cannabinoid medicines, including Sativex, to meet patient needs in a wide range of therapeutic indications. The principal initial target areas are Multiple Sclerois (MS) spasticity, neuropathic pain, neuropathic pain in MS and cancer pain. The Group's research also includes the use of other controlled drugs in conjunction with its proprietary secure drug dispensing technology. The Group operates predominantly in the United Kingdom.
Competitor Analysis
This analysis compares GW Pharmaceuticals PLC with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
